• Hero Banner
  • ACVCACVC
  • DVM 360
  • Fetch DVM 360Fetch DVM 360
DVM 360
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
By Role
AssociatesOwnersPractice ManagerStudentsTechnicians
Subscriptions
dvm360 Newsletterdvm360 Magazine
News
All News
Association
Breaking News
Education
Equine
FDA
Law & Ethics
Market Trends
Medical
Products
Recalls
Regulatory
Digital Media
dvm360 LIVE!™
Expert Interviews
The Vet Blast Podcast
Medical World News
Pet Connections
The Dilemma Live
Vet Perspectives™
Weekly Newscast
dvm360 Insights™
Publications
All Publications
dvm360
Firstline
Supplements
Top Recommended Veterinary Products
Vetted
Clinical
All Clinical
Anesthesia
Animal Welfare
Behavior
Cardiology
CBD in Pets
Dentistry
Dermatology
Diabetes
Emergency & Critical Care
Endocrinology
Equine Medicine
Exotic Animal Medicine
Feline Medicine
Gastroenterology
Imaging
Infectious Diseases
Integrative Medicine
Nutrition
Oncology
Ophthalmology
Orthopedics
Pain Management
Parasitology
Pharmacy
Surgery
Toxicology
Urology & Nephrology
Virtual Care
Business
All Business
Business & Personal Finance
Buying or Selling a Practice
Hospital Design
Leadership & Personal Growth
Personnel Management
Practice Finances
Practice Operations
Technology
Wellbeing & Lifestyle
Continuing Education
Conferences
Live Conferences
Conference News
Conference Proceedings
Resources
CBD in Pets
Contests
Veterinary Heroes
Partners
Spotlight Series
Team Meeting in a Box
Toolkit
Top Recommended Veterinary Products
Vet to Vet
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us

© 2023 MJH Life Sciences and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

Advertisement
By Role
  • Associates
  • Owners
  • Practice Manager
  • Students
  • Technicians
Subscriptions
  • dvm360 Newsletter
  • dvm360 Magazine
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us
  • MJHLS Brand Logo

© 2023 MJH Life Sciences™ and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

Cannabinoid Product Shown to Increase Comfort, Activity in Dogs With OA

August 28, 2018
Kerry Lengyel

Findings from a new study show the benefits of cannabidiol-based oil in dogs with osteoarthritis and multi-joint pain.

Dogs suffering from osteoarthritis (OA) are usually prescribed nonsteroidal anti-inflammatory drugs (NSAIDs), but NSAIDs sometimes are insufficient in alleviating pain and also have potential adverse effects, particularly in older pets with certain comorbidities.

Late last year, ElleVet Sciences—a US manufacturer of cannabinoid-based soft chews and oil products for dogs and cats—launched what has been dubbed a “game-changing” canine mobility supplement made from a proprietary hemp oil blend.

RELATED:

  • Current Options for Managing Canine Osteoarthritis
  • Medical Marijuana Research Remains Top Priority for Veterinarians

Now, with help from investigators at the Cornell University College of Veterinary Medicine, the findings of the first pharmacokinetic, safety, and efficacy study on the use of this cannabidiol (CBD) oil in dogs with OA pain have been published in the journal Frontiers.

Pharmacokinetic Study

To determine single-dose oral pharmacokinetics and short-term safety of ElleVet’s CBD product, investigators first performed a pharmacokinetic study on 4 beagles. Each dog received 2 treatments—2 and 8 mg/kg of CBD oil—with a 2-week washout period between treatments.

Advertisement

A physical examination was performed at 0, 4, 8, and 24 hours after treatment, and blood samples were taken at 0, 0.5, 1, 2, 4, 8, 12, and 24 hours after treatment.

Results showed no obvious psychoactive properties or side effects at any times for either dose over 24 hours. In addition, the terminal half-life of oral CBD was 4 to 5 hours, suggesting bioavailability with a dosing schedule of 2 mg/kg at least twice daily.

Clinical Trial

Next, investigators conducted a clinical trial with 16 client-owned dogs with clinically and radiographically confirmed OA. Each dog received 2 treatments—2 mg/kg of CBD oil every 12 hours and placebo oil every 12 hours—in random order. Each treatment was administered for 4 weeks with a 2-week washout period between treatments.

Blood was collected and a chemistry analysis completed for each dog at weeks 2 and 4 for both treatment arms. Dogs were also evaluated based on the Canine Brief Pain Inventory (CBPI) and the Hudson activity scale by a veterinarian and the owner before the treatments began and at weeks 2 and 4.

Results showed a significant decrease in pain and an increase in activity at weeks 2 and 4 during CBD treatment compared with pretreatment baselines. Owners reported no side effects, but serum chemistry did show an increase in alkaline phosphatase during CBD treatment.

Summary

Even with the small sample size and short study duration, the investigators concluded that 2 mg/kg of CBD oil twice daily can help increase comfort and activity level in dogs with OA.

ElleVet is planning a long-term safety and pharmacokinetic study on cats to launch a new product—ElleVet Feline—as well as 3 additional clinical trials in fall 2018 in partnership with the University of Florida.


Advertisement

Latest News

Four ways to curb no shows

FDA and European Union expand Mutual Recognition Agreement to include animal drugs

Successful tolerability study of CBD products for dogs

Second annual 'Dog Days of Summer' adoption event to take place in Michigan

View More Latest News
Advertisement